Article Information
History
- June 30, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Deborah Cromer1,
- Arnold Reynaldi1,
- Megan Steain2,3,
- James A Triccas2,3,
- Miles P Davenport1,# and
- David S Khoury1,#
- 1Kirby Institute, University of New South Wales, Sydney, Australia
- 2School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- 3Sydney Institute of Infectious Diseases and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
- ↵#Corresponding author: m.davenport{at}unsw.edu.au; dkhoury{at}kirby.unsw.edu.au
Posted June 30, 2021.
Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial
